Yang Zhan, Ph.D.

• Designed overall strategy and direction of preclinical and early clinical trials to meet regulatory requirements, ultimately to meet the project needs for clients; • Supervised and monitored multiple disciplinary activities for sponsors including pharmacology, DMPK, Toxicology studies, CMC, regulatory writing and IND submission within expected timeline; • Defined scope of work and generated timeline for the IND enabling project while working closely with the client and internal project team. • Kept clients and project team updated in a timely manner regarding progress of projects and decision points to facilitate the project development through regular teleconferences, e-mails, site visits or other suitable means. • Prepared the regulatory submission documents and dossier writing for pharmacology, DMPK and safety assessment parts. • Identified potential issues and input the constructive suggestions.

• Led the optimization stage in drug discovery of small-molecule projects. • Directed biology and DMPK groups to design and improve the profiles of small molecules for selection of high-quality preclinical candidates. • Independently designed structures of biologically active molecules to conduct SAR studies. • Managed the external chemistry team (CRO, 15 FTEs) in the synthesis and characterization of drug candidates. • Coordinated with the computational chemistry group to develop structure-based modifications. • Skilled in scientific instrument [analysis and spectroscopic techniques (NMR, HPLC/UPLC, MS, LC-MS, IR, UV); structure-based modification software: MOE, Schrödinger] • GSK Exceptional Science Award